Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateSep 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Regulation FD

TL;DR

GALECTIN THERAPEUTICS INC. filed a standard 8-K on 9/8/25. No major news.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for this date.

Why It Matters

This filing indicates routine corporate reporting by Galectin Therapeutics Inc. to the SEC, without disclosing new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information, specific financial disclosures, or significant events that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Galectin Therapeutics Inc. on September 8, 2025?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is September 8, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.

What is the registrant's telephone number?

The registrant's telephone number is (678) 620-3186.

What is the company's former name and when was the name change date?

The company's former name was PRO PHARMACEUTICALS INC, and the date of the name change was June 12, 2001.

Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-08 07:56:25

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 8, 2025, Galectin Therapeutics Inc. (the "Company") posted to its website an updated Corporate Presentation attached hereto as Exhibit 99.1. A copy of the presentation is furnished herewith as Exhibit 99.1 and incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01 of this Current Report on Form 8-K and the exhibits attached hereto are deemed to be "furnished" and shall not be deemed "filed" for the purpose of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. This Current Report on Form 8-K and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit Description 99.1 Galectin Therapeutic Inc. Corporate Presentation, updated September 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: September 8, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing